Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesOne year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçets disease refractory to standard immunosuppressive drugs
Rheumatology International, 10/30/09
Giardina AR et al. – The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents.
Methods- 21 patients that did not respond to corticosteroids and to at least 1 immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for presence of ocular and/or CNS involvement enrolled
- 18 patients completed study up to 54 weeks
- Stable doses of prednisone (<10 mg/day) permitted, immunosuppressants discontinued at least 4 weeks prior baseline visit
- Patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and infusions of 5 mg/kg Infliximab every 8 weeks
- At each visit data on clinical symptoms, response to therapy and adverse events collected
- Primary outcome of interest to assess clinical efficacy (total or partial recovery) of infliximab
- Secondary end points were to evaluate quality of life and monitor safety of drug
- 18 patients achieved total remission
- 2 patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy
- Infliximab well tolerated
- Case of non-Hodgkin lymphoma observed within 6 months
- Minor side effects were headache, dizziness, tachycardia that regressed spontaneously and did not entail interruption
- Anti-nuclear antibodies not detected during period of observation
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome
Diabetes Care, 11/25/09
Low-Density Lipoprotein Cholesterol Reduction and Goal Achievement With Ezetimibe/Simvastatin Versus Atorvastatin or Rosuvastatin in Patients With Diabetes, Metabolic Syndrome, or Neither Disease, Stratified By National Cholesterol Education Program Risk Category
Metabolic Syndrome and Related Disorders, 11/25/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effect of alendronate on bone metabolic indices and bone mineral density in patients treated with high-dose glucocorticoid: A prospective study
Osteoporosis International, 11/25/09
Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Prevalent vertebral deformity independently increases incident vertebral fracture risk in middle-aged and elderly Japanese women: The Japanese Population-based Osteoporosis (JPOS) Cohort Study
Osteoporosis International, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor